ICON plc - Ordinary Shares (ICLR): Price and Financial Metrics

ICON plc - Ordinary Shares (ICLR): $244.08

-2.47 (-1.00%)

POWR Rating

Component Grades














  • Growth is the dimension where ICLR ranks best; there it ranks ahead of 92.99% of US stocks.
  • The strongest trend for ICLR is in Momentum, which has been heading down over the past 31 weeks.
  • ICLR's current lowest rank is in the Sentiment metric (where it is better than 24.7% of US stocks).

ICLR Stock Summary

  • Icon Plc's market capitalization of $12,155,514,175 is ahead of 83.25% of US-listed equities.
  • Revenue growth over the past 12 months for Icon Plc comes in at 67.86%, a number that bests 91.55% of the US stocks we're tracking.
  • The volatility of Icon Plc's share price is greater than that of merely 11.32% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Icon Plc, a group of peers worth examining would be MORN, CIEN, PNR, AMED, and MKSI.
  • Visit ICLR's SEC page to see the company's official filings. To visit the company's web site, go to www.iconplc.com.

ICLR Valuation Summary

  • In comparison to the median Healthcare stock, ICLR's price/sales ratio is 13.89% higher, now standing at 4.1.
  • Over the past 216 months, ICLR's price/sales ratio has gone up 2.
  • Over the past 216 months, ICLR's price/sales ratio has gone up 2.

Below are key valuation metrics over time for ICLR.

Stock Date P/S P/B P/E EV/EBIT
ICLR 2019-01-02 3.9 5.8 24.5 20.5
ICLR 2015-09-03 3.0 4.8 26.4 21.8
ICLR 2015-09-01 3.0 4.7 26.2 21.6
ICLR 2009-01-23 1.8 2.9 20.2 15.7
ICLR 2004-12-21 1.8 2.4 20.5 13.5
ICLR 2004-04-20 2.2 3.7 27.6 19.3

ICLR Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at 119.15%.
  • Its 5 year price growth rate is now at 170.05%.
  • Its 2 year price growth rate is now at 37.06%.
Over the past 61 months, ICLR's revenue has gone up $1,222,310,000.

The table below shows ICLR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 2,797.288 568.035 332.331
2019-12-31 2,805.839 412.541 373.986
2018-12-31 2,595.777 268.639 322.656
2017-12-31 1,758.439 383.082 281.488
2016-12-31 1,666.487 259.204 262.179
2015-12-31 1,574.978 279.531 239.539

ICLR Price Target

For more insight on analysts targets of ICLR, see our ICLR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $205.14 Average Broker Recommendation 1.72 (Moderate Buy)

ICLR Stock Price Chart Interactive Chart >

Price chart for ICLR

ICLR Price/Volume Stats

Current price $244.08 52-week high $250.24
Prev. close $246.55 52-week low $168.76
Day low $242.29 Volume 1,925,300
Day high $250.24 Avg. volume 753,063
50-day MA $218.89 Dividend yield N/A
200-day MA $204.75 Market Cap 12.90B

ICON plc - Ordinary Shares (ICLR) Company Bio

ICON Public Limited Company provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company was founded in 1990 and is based in Dublin, Ireland.

ICLR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$244.08$140.92 -39%

We started the process of determining a valid price forecast for Icon Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Icon Plc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Icon Plc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 30.2 -- which is good for besting 83.55% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately just 13.53% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • ICLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.09% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Icon Plc? See ICUI, VIVO, UTHR, ABT, and FZMD.

ICLR Latest News Stream

Event/Time News Detail
Loading, please wait...

ICLR Latest Social Stream

Loading social stream, please wait...

View Full ICLR Social Stream

Latest ICLR News From Around the Web

Below are the latest news stories about Icon Plc that investors may wish to consider to help them evaluate ICLR as an investment opportunity.

Icon PLC (ICLR) Soars to 52-Week High, Time to Cash Out?

Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Yahoo | July 30, 2021

Surging Earnings Estimates Signal Upside for Icon PLC (ICLR) Stock

Icon PLC (ICLR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Yahoo | July 29, 2021

Top Ranked Growth Stocks to Buy for July 26th

ICLR, DG, AN, and DVN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 26, 2021

Yahoo | July 26, 2021

New Strong Buy Stocks for July 26th

CRK, MATX, RGP, ESTE, and ICLR have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2021.

Yahoo | July 26, 2021

Pharmacovigilance Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Eli Lilly and Company, ICON plc, Elsevier, Chiltern, Atlantic Research Group, Mapi Group, Acce

This report studies the Pharmacovigilance Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Pharmacovigilance market segmented by company, region, type and applications []

Jumbo News | July 24, 2021

Read More 'ICLR' Stories Here

ICLR Price Returns

1-mo 13.48%
3-mo 9.96%
6-mo 22.33%
1-year 29.50%
3-year 69.57%
5-year 218.56%
YTD 25.18%
2020 13.21%
2019 33.29%
2018 15.21%
2017 49.14%
2016 -3.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8232 seconds.